These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 2732632

  • 1. Iron excretion in thalassemia children treated with deferoxamin methansulfonat: intravenous drip compared to the subcutaneous routes.
    Hathirat P, Areekul S, Isarangkura P, Chantachum Y.
    J Med Assoc Thai; 1989 Jan; 72 Suppl 1():121-4. PubMed ID: 2732632
    [Abstract] [Full Text] [Related]

  • 2. [Intravenous administration of deferoxamine in over-night hospitalization: efficacy and good psychological tolerance in thalassemic children].
    Bachelot C, Plantaz D.
    Pediatrie; 1990 Jan; 45(9):619-23. PubMed ID: 2175425
    [Abstract] [Full Text] [Related]

  • 3. The simple rubber band technic for slow subcutaneous infusion of desferrioxamine.
    Hathirat P, Sasanakul W, Areekul S, Chantachum Y, Isarangkura P.
    J Med Assoc Thai; 1984 Feb; 67(2):89-92. PubMed ID: 6736830
    [No Abstract] [Full Text] [Related]

  • 4. Effect of subcutaneous deferoxamine and oral vitamin C on iron excretion in congenital hypoplastic anemia and refractory anemia associated with the 5q-syndrome.
    Ambruso DR, Mahony BS, Githens JH, Rhoades ED.
    Am J Pediatr Hematol Oncol; 1982 Feb; 4(2):115-23. PubMed ID: 7114394
    [Abstract] [Full Text] [Related]

  • 5. Iron chelation therapy with deferoxamine in Cooley anemia.
    Cohen A, Schwartz E.
    J Pediatr; 1978 Apr; 92(4):643-7. PubMed ID: 633031
    [Abstract] [Full Text] [Related]

  • 6. Rubber band technique for slow subcutaneous infusion of desferrioxamine (Desferal).
    Hathirat P, Isarangkura P, Panthangkura W, Chuansumrit A, Sasanakul W, Kanasit R.
    Birth Defects Orig Artic Ser; 1988 Apr; 23(5B):123-7. PubMed ID: 3390534
    [Abstract] [Full Text] [Related]

  • 7. [Effect of two years of deferoxamine therapy on iron balance, ferritin, liver and heart in patients with thalassemia major].
    Flückiger A, Imbach P, Pfenninger E, Stocker F, Töndury P, Wagner HP, Weber J, Zuppinger K.
    Helv Paediatr Acta; 1985 Sep; 40(4):293-304. PubMed ID: 4077563
    [Abstract] [Full Text] [Related]

  • 8. Subcutaneous bolus injection of deferoxamine in adult patients affected by onco-hematologic diseases and iron overload.
    Borgna-Pignatti C, Franchini M, Gandini G, Vassanelli A, De Gironcoli M, Aprili G.
    Haematologica; 1998 Sep; 83(9):788-90. PubMed ID: 9825575
    [Abstract] [Full Text] [Related]

  • 9. [Desferrioxamine in thalassemia].
    Biener R, Freundlich E, Rachmilewitz E.
    Harefuah; 1983 May 15; 104(10):438-40. PubMed ID: 6629159
    [No Abstract] [Full Text] [Related]

  • 10. Chelation therapy in beta-thalassemia major. I. Intravenous and subcutaneous deferoxamine.
    Graziano JH, Markenson A, Miller DR, Chang H, Bestak M, Meyers P, Pisciotto P, Rifkind A.
    J Pediatr; 1978 Apr 15; 92(4):648-52. PubMed ID: 633032
    [No Abstract] [Full Text] [Related]

  • 11. Intensive long-term intravenous iron-chelation therapy with deferoxamine in thalassemic patients.
    Cianciulli P, Forte L, Sorrentino F, Palombi M, Papa G, Marciani MG.
    Bone Marrow Transplant; 1993 Apr 15; 12 Suppl 1():5-8. PubMed ID: 8374563
    [No Abstract] [Full Text] [Related]

  • 12. Continuous subcutaneous administration of deferoxamine in patients with iron overload.
    Propper RD, Cooper B, Rufo RR, Nienhuis AW, Anderson WF, Bunn HF, Rosenthal A, Nathan DG.
    N Engl J Med; 1977 Aug 25; 297(8):418-23. PubMed ID: 882111
    [Abstract] [Full Text] [Related]

  • 13. [Chelating therapy in beta-thalassemia].
    Musumeci S, Romeo MA, Di Gregorio F, Schiliró G, Russo G.
    Pediatr Med Chir; 1982 Aug 25; 4(1-2):55-9. PubMed ID: 7111040
    [Abstract] [Full Text] [Related]

  • 14. Desferrioxamine induced urinary iron excretion in thalassemia.
    Dubey AP, Kumar S, Choudhury P, Talukdar B, Puri RK.
    Indian Pediatr; 1993 Jun 25; 30(6):775-8. PubMed ID: 8132258
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Study of intermittent intravenous deferrioxamine high-dose therapy in heavily iron-loaded children with beta-thalassemia major poorly compliant to subcutaneous injections.
    Wali YA, Taqi A, Deghaidi A.
    Pediatr Hematol Oncol; 2004 Jun 25; 21(5):453-60. PubMed ID: 15205089
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Iron status in thalassemia major patients after long-term subcutaneous desferrioxamine.
    Kontopoulou-Griva I, Hatzidimitriou-Papazacharia K, Spiliotopoulou J, Tsagarakis N, Digenopoulou E.
    Birth Defects Orig Artic Ser; 1988 Jun 25; 23(5B):111-6. PubMed ID: 3390532
    [No Abstract] [Full Text] [Related]

  • 20. High-dose intravenous chelation therapy with deferoxamine.
    Cohen A, Mizanin J, Schwartz E.
    Prog Clin Biol Res; 1989 Jun 25; 309():125-31. PubMed ID: 2780746
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.